BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 26544511)

  • 1. Degradation of the cancer genomic DNA deaminase APOBEC3B by SIV Vif.
    Land AM; Wang J; Law EK; Aberle R; Kirmaier A; Krupp A; Johnson WE; Harris RS
    Oncotarget; 2015 Nov; 6(37):39969-79. PubMed ID: 26544511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simian Immunodeficiency Virus Vif and Human APOBEC3B Interactions Resemble Those between HIV-1 Vif and Human APOBEC3G.
    Wang J; Shaban NM; Land AM; Brown WL; Harris RS
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29618650
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOBEC3B and APOBEC3C are potent inhibitors of simian immunodeficiency virus replication.
    Yu Q; Chen D; König R; Mariani R; Unutmaz D; Landau NR
    J Biol Chem; 2004 Dec; 279(51):53379-86. PubMed ID: 15466872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vif hijacks CBF-β to degrade APOBEC3G and promote HIV-1 infection.
    Jäger S; Kim DY; Hultquist JF; Shindo K; LaRue RS; Kwon E; Li M; Anderson BD; Yen L; Stanley D; Mahon C; Kane J; Franks-Skiba K; Cimermancic P; Burlingame A; Sali A; Craik CS; Harris RS; Gross JD; Krogan NJ
    Nature; 2011 Dec; 481(7381):371-5. PubMed ID: 22190037
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif.
    Pery E; Rajendran KS; Brazier AJ; Gabuzda D
    J Virol; 2009 Mar; 83(5):2374-81. PubMed ID: 19109396
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vif Proteins from Diverse Human Immunodeficiency Virus/Simian Immunodeficiency Virus Lineages Have Distinct Binding Sites in A3C.
    Zhang Z; Gu Q; Jaguva Vasudevan AA; Jeyaraj M; Schmidt S; Zielonka J; Perković M; Heckel JO; Cichutek K; Häussinger D; Smits SHJ; Münk C
    J Virol; 2016 Nov; 90(22):10193-10208. PubMed ID: 27581978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HIV-2 Vif and foamy virus Bet antagonize APOBEC3B by different mechanisms.
    Zhang Z; Perković M; Gu Q; Balakrishnan K; Sangwiman A; Häussinger D; Lindemann D; Münk C
    Virology; 2021 Feb; 554():17-27. PubMed ID: 33333348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conserved and non-conserved features of HIV-1 and SIVagm Vif mediated suppression of APOBEC3 cytidine deaminases.
    Zhang W; Huang M; Wang T; Tan L; Tian C; Yu X; Kong W; Yu XF
    Cell Microbiol; 2008 Aug; 10(8):1662-75. PubMed ID: 18419775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endogenous origins of HIV-1 G-to-A hypermutation and restriction in the nonpermissive T cell line CEM2n.
    Refsland EW; Hultquist JF; Harris RS
    PLoS Pathog; 2012; 8(7):e1002800. PubMed ID: 22807680
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of conserved motifs in HIV-1 Vif required for APOBEC3G and APOBEC3F interaction.
    He Z; Zhang W; Chen G; Xu R; Yu XF
    J Mol Biol; 2008 Sep; 381(4):1000-11. PubMed ID: 18619467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of efficient degradation of APOBEC3 restriction factors by HIV-1 Vif.
    Baig TT; Feng Y; Chelico L
    J Virol; 2014 Dec; 88(24):14380-95. PubMed ID: 25275135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1.
    Hultquist JF; Lengyel JA; Refsland EW; LaRue RS; Lackey L; Brown WL; Harris RS
    J Virol; 2011 Nov; 85(21):11220-34. PubMed ID: 21835787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Catalytic activity of APOBEC3F is required for efficient restriction of Vif-deficient human immunodeficiency virus.
    Albin JS; Brown WL; Harris RS
    Virology; 2014 Feb; 450-451():49-54. PubMed ID: 24503066
    [TBL] [Abstract][Full Text] [Related]  

  • 14. APOBEC3B Potently Restricts HIV-2 but Not HIV-1 in a Vif-Dependent Manner.
    Bandarra S; Miyagi E; Ribeiro AC; Gonçalves J; Strebel K; Barahona I
    J Virol; 2021 Nov; 95(23):e0117021. PubMed ID: 34523960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F.
    Russell RA; Pathak VK
    J Virol; 2007 Aug; 81(15):8201-10. PubMed ID: 17522216
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif.
    Doehle BP; Schäfer A; Cullen BR
    Virology; 2005 Sep; 339(2):281-8. PubMed ID: 15993456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.
    Liu B; Yu X; Luo K; Yu Y; Yu XF
    J Virol; 2004 Feb; 78(4):2072-81. PubMed ID: 14747572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vif proteins of human and simian immunodeficiency viruses require cellular CBFβ to degrade APOBEC3 restriction factors.
    Hultquist JF; Binka M; LaRue RS; Simon V; Harris RS
    J Virol; 2012 Mar; 86(5):2874-7. PubMed ID: 22205746
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H.
    Binka M; Ooms M; Steward M; Simon V
    J Virol; 2012 Jan; 86(1):49-59. PubMed ID: 22013041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of 81LGxGxxIxW89 and 171EDRW174 domains from human immunodeficiency virus type 1 Vif that regulate APOBEC3G and APOBEC3F neutralizing activity.
    Dang Y; Davis RW; York IA; Zheng YH
    J Virol; 2010 Jun; 84(11):5741-50. PubMed ID: 20335268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.